ReviewGut2005
Barrett's oesophagus: from metaplasia to dysplasia and cancer.
Review in Gut, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 1 synthesis or guideline pooled it, 184 citations in OpenAlex.
- Chemoprevention of Barrett's Esophagus: a Systematic Review and Comprehensive Assessment of Bias.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2025Pooled it
- Benefit of baseline cytometry for surveillance of patients with Barrett's esophagus.Surgical endoscopy · 2010Trial
- Optimal cannabinoid-terpene combination ratios suppress mutagenicity of gastric reflux in normal and metaplastic esophageal cells.World journal of gastroenterology · 2026Article
- Tetrahydroxylated bile acids prevents malignant progression of Barret esophagusWorld journal of gastroenterology · 2025Article
- Histopathological Assessment of the Endoscopic Resection Specimen.Visceral medicine · 2024Review
- Guanylyl cyclase C as a diagnostic and therapeutic target in colorectal cancer.Personalized medicine · 2022Review
- Targeted genetic and epigenetic profiling of esophageal adenocarcinomas and non-dysplastic Barrett's esophagus.Clinical epigenetics · 2022Article
- The Use of miRNAs in Predicting Response to Neoadjuvant Therapy in Oesophageal Cancer.Cancers · 2022Review
- Equine Squamous Gastric Disease: Prevalence, Impact and Management.Veterinary medicine (Auckland, N.Z.) · 2021Review
- Is Malignant Potential of Barrett's Esophagus Predictable by Endoscopy Findings?Life (Basel, Switzerland) · 2020Review
- Molecular Profile of Barrett's Esophagus and Gastroesophageal Reflux Disease in the Development of Translational Physiological and Pharmacological Studies.International journal of molecular sciences · 2020Article
- Minichromosomal Maintenance Component Complex 5 (MCM5) as a Marker of Barrett's Esophagus-Related Neoplasia: A Feasibility Study.Digestive diseases and sciences · 2019Article
- Understanding optical reflectance contrast for real-time characterization of epithelial precursor lesions.Bioengineering & translational medicine · 2019Article
- Article
- Barrett's esophagus with high grade dysplasia is associated with non-esophageal cancer.World journal of gastroenterology · 2018Article
- Molecular Evolution of Metaplasia to Adenocarcinoma in the Esophagus.Digestive diseases and sciences · 2018Review
- Development of Novel Monoclonal Antibodies for Evaluation of Transmembrane Prostate Androgen-Induced Protein 1 (TMEPAI) Expression Patterns in Gastric Cancer.Pathology oncology research : POR · 2018Article
- Interorgan regulation ofDevelopment (Cambridge, England) · 2017Article
- Barrett's oesophagus: Current controversies.World journal of gastroenterology · 2017Review
- Evolutionary dynamics in pre-invasive neoplasia.Current opinion in systems biology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Barrett's oesophagus is a premalignant condition that predisposes to the development of oesophageal adenocarcinoma. It is detected on endoscopy and confirmed histologically by the presence in the lower oesophagus of a metaplastic mucosa, the so-called specialised epithelium, which resembles incomplete intestinal metaplasia in the stomach. These similarities with incomplete intestinal metaplasia are present on histology, mucin histochemistry, and immunohistochemistry with various differentiation markers (cytokeratins and MUC antigens). On morphology, the carcinogenetic process of Barrett's mucosa progresses through increasing grades of epithelial dysplasia. Dysplasia, a synonym of intraepithelial neoplasia, is the only marker that can be used at the present time to delineate a population of patients at high risk of cancer. Among the numerous molecular events that have been shown to play a role in the neoplastic transformation of Barrett's mucosa, only changes in DNA ploidy, increased proliferation, and alterations of the p53 gene have been suggested to be of potential help in the surveillance of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.